<DOC>
	<DOCNO>NCT01435226</DOCNO>
	<brief_summary>This Phase 2 Randomized , Double-Blind , Placebo-Controlled Study GS-5885 , GS-9451 , Tegobuvir Ribavirin ( RBV ) Compared GS-5885 , GS-9451 Tegobuvir RBV Treatment-Experienced Subjects Chronic Genotype 1a 1b Hepatitis C Virus ( HCV ) Infection .</brief_summary>
	<brief_title>GS-5885 , GS-9451 , Tegobuvir Ribovirin Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Age ≥18 year chronic HCV infection Liver biopsy result ≤ 3 year prior screen indicate absence cirrhosis . Alternatively , noninvasive procedure conduct within 6 month screen permitted country allow Monoinfection HCV genotype ( GT ) 1a 1b HCV RNA ≥ 104 IU/mL screen Prior treatment adherence one course pegylated interferon alfa RBV The subject 's medical record must include sufficient detail prior treatment pegylated interferon alfa RBV ( start/stop date viral response ) allow categorization prior response either null , partial , breakthrough relapse . Body mass index ( BMI ) 1840 kg/m2 inclusive Screening ECG without clinically significant abnormality QTcF interval ( QT correct use Fridericia 's formula ) ≤ 450 msec male ≤ 470 msec female . Agree use two form highly effective contraception duration study 7 month last dose study medication . Females childbearing potential must negative pregnancy test screen baseline . Discontinuation prior treatment pegylated interferon alfa RBV due adverse event , toxicity reason lose followup History significant cardiac disease Exceed criterion delineate Section 4.2 laboratory measure threshold relate leukopenia , neutropenia , anemia , thrombocytopenia , thyroid stimulate hormone ( TSH ) . Diagnosis autoimmune disease , decompensated liver disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , HIV , hepatitis B virus ( HBV ) , hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) , hemoglobinopathy , retinal disease , immunosuppressed . Current abuse amphetamine , cocaine , opiates , alcohol . Methadone use allow , however stable buprenorphine maintenance treatment ≥ 6 month permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Interferon intolerant</keyword>
	<keyword>Interferon ineligible</keyword>
	<keyword>GS-9190</keyword>
	<keyword>GS-9451</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Chronic Genotype 1a 1b</keyword>
</DOC>